This announcement is a separate document:
君实生物自愿披露关于特瑞普利单抗用于晚期三阴性乳腺癌一线治疗的新适应症上市申请获得批准的公告
Junshi Bio voluntarily discloses the announcement of the approval of the new indication for Teriprizumab monoclonal antibody for first-line treatment of advanced Triple-Negative Breast Cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated